Regeneron Pharmaceuticals, Inc.
$815.15
+1.88 · +0.23% today
Market open · updated 12:44:26 PM ET
- High
- $819.99 11:25 AM
- Low
- $806.63 9:40 AM
Against the S&P 500 Price change through Oct 27, 2026
REGN+5.73%
S&P 500+12.87%
REGN+39.43%
S&P 500+12.32%
REGN+5.28%
S&P 500+87.41%
REGN+38.42%
S&P 500+69.55%
Key numbers
- Previous close
- $813.27
- Open
- $826.14
- Day's range
- $813.00 – $828.19
- 52-week range
- $591.52 – $859.34
- Volume
- 358,664
- Average volume
- 785,412
- Market value
- $83.9 billion
- Price to earnings
- 19.3last 12 months
- Earnings per share
- $41.86last 12 months
- Beta
- 0.24moves less than the market
- Dividend
- $3.70 a year · 0.46%
- 50-day average
- $791.72
- 200-day average
- $736.37
Friday, Oct 30, 2026, before the open.
Analyst price targets and the full financials are in the terminal.
Who Regeneron Pharmaceuticals competes with From our value chain
Regeneron Pharmaceuticals in the news
- HeadlineRegeneron Earnings Preview: Dupixent Is Booming, But It's Still OvervaluedSeeking Alpha · October 28, 2026 at 7:43 AM ET
- HeadlineHere's Why Regeneron (REGN) is a Strong Value StockZacks Investment Research · October 26, 2026 at 10:41 AM ET
- HeadlineRegeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. PreparednessGlobeNewsWire · October 26, 2026 at 7:00 AM ET
- Week aheadWeek Ahead: Fed Decision, GDP, PCE Inflation and Peak Earnings WeekWiseView Research desk · October 25, 2026
- HeadlineRegeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research · October 23, 2026 at 11:01 AM ET
- HeadlineRegeneron: Is The Market Undervaluing Its Growth PotentialSeeking Alpha · October 22, 2026 at 9:45 AM ET
- HeadlineForget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss MarketThe Motley Fool · October 19, 2026 at 10:24 AM ET
- HeadlineForget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit ShareThe Motley Fool · October 17, 2026 at 3:24 PM ET
Earnings
Next report: Friday, Oct 30, 2026, before the open.
Congress trades in REGN
5 purchases and 3 sales in the latest 8 filings.
| Member | Trade | Amount | Traded | Disclosed |
|---|---|---|---|---|
| Ro KhannaHouse · D-California | Sale | $1,001 - $15,000 | Sep 4, 2026 | Oct 9, 2026 |
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Jul 7, 2026 | Aug 12, 2026 |
| Alan ArmstrongSenate · R-Oklahoma | Purchase | $1,001 - $15,000 | Mar 27, 2026 | Jul 22, 2026 |
| Gilbert CisnerosHouse · D-California | Sale | $1,001 - $15,000 | May 15, 2026 | Jun 9, 2026 |
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Apr 13, 2026 | May 13, 2026 |
| Julia LetlowHouse · R-Louisiana | Purchase | $1,001 - $15,000 | Feb 12, 2026 | Mar 13, 2026 |
| Ro KhannaHouse · D-California | Sale | $1,001 - $15,000 | Sep 29, 2025 | Oct 3, 2025 |
| Ro KhannaHouse · D-California | Purchase | $1,001 - $15,000 | Aug 26, 2025 | Sep 12, 2025 |
Source: Periodic transaction reports filed with the House and the Senate · Members disclose ranges, not exact amounts, and may file weeks after the trade.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses.
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15,410
- Headquarters
- Tarrytown, New York
- Website
- regeneron.com
- Listed
- Apr 2, 1991
More biotechnology stocks
The price refreshes every 15 seconds while the market is open and carries the time it was read. Company figures are updated each evening. Built from WiseView and market data and public filings. For information only, not investment advice.